Kits for local delivery of water soluble agents and methods of use
A kit includes a mesh substrate and a polymer that is fixed to the mesh substrate. The polymer includes an active agent that is configured to elute over time. The kit further includes a hemostatic agent. The hemostatic agent is separate from the mesh substrate and the polymer. Systems and methods are disclosed.
1. A kit comprising:
a medical device;
a substrate defining a pocket configured to receive the medical device, the substrate comprising interlocked fibers that define multiple pores between adjacent fibers, the substrate being at least partially coated with a polymer that includes at least one active pharmaceutical agent, the polymer being configured to elute the at least one active pharmaceutical agent over time; and
a hemostatic agent,
wherein the substrate is disposed in a first package and the hemostatic agent is disposed in a second package that is separate from the first package.
2. A kit as recited in claim 1 , wherein the substrate comprises apertures that extend through the fibers, the apertures being larger than the pores.
3. A kit as recited in claim 1 , wherein the substrate comprises apertures that are formed by cutting the fibers.
4. A kit as recited in claim 1 , wherein the substrate is made entirely from a non-biodegradable material.
5. A kit as recited in claim 1 , wherein the substrate is made entirely from a biodegradable material.
6. A kit as recited in claim 1 , wherein the substrate comprises a first piece and a second piece that is joined with the first piece along three sides of the pocket.
7. A kit as recited in claim 1 , wherein the substrate is at least partially coated with multiple coating layers of the polymer.
8. A kit as recited in claim 7 , wherein the coating layers each include the same amount of the active pharmaceutical agent.
9. A kit as recited in claim 7 , wherein the coating layers include different amounts of the active pharmaceutical agent.
10. A kit as recited in claim 1 , wherein the polymer is free of hemostatic agents.
11. A kit as recited in claim 1 , wherein the active pharmaceutical agent includes rifampin and minocycline.
12. A kit as recited in claim 1 , wherein the amount of the active pharmaceutical agent that is applied to the substrate via the polymer ranges between about 0.3 to about 150 micrograms/cm 2 .
13. A kit as recited in claim 1 , wherein the active pharmaceutical agent includes rifampin and minocycline and the amount of each of rifampin and minocycline that is applied to the substrate via the polymer ranges between about 0.6 to about 1.4 micrograms/cm 2 .
14. A kit as recited in claim 1 , wherein the polymer comprises a tyrosine-derived polyesteramide.
15. A kit as recited in claim 1 , wherein the polymer comprises a tyrosine-derived polyesteramide and the active pharmaceutical agent includes rifampin and minocycline.
16. A kit comprising:
a medical device;
a substrate defining a pocket configured to receive the medical device;
a hydrophilic component and a crosslinking agent that are applied to the substrate, the substrate being at least partially coated with a polymer that includes at least one active pharmaceutical agent, the polymer being configured to elute the at least one active pharmaceutical agent over time; and
a hemostatic agent,
wherein the substrate is disposed in a first package and the hemostatic agent is disposed in a second package that is separate from the first package.
17. A kit as recited in claim 16 , wherein the hydrophilic component comprises polyethylene glycol.
18. A kit as recited in claim 16 , wherein the hydrophilic component and the crosslinking agent are applied to the substrate in the polymer.
19. A kit as recited in claim 16 , wherein the hydrophilic component and the crosslinking agent are applied to the substrate in a patch.
20. A kit comprising:
a medical device;
a substrate defining a pocket configured to receive the medical device, the substrate comprising polyethylene glycol and a crosslinking agent, the substrate being at least partially coated with a tyrosine-derived polyesteramide polymer that includes a combination of rifampin and minocycline, the polymer being configured to elute the rifampin and minocycline over time; and
a hemostatic agent,
wherein the polyethylene glycol and the crosslinking agent form a hydrogel that absorbs blood and reduces bleeding when in contact with blood, and
wherein the substrate is disposed in a first package and the hemostatic agent is disposed in a second package that is separate from the first package.